New video discussion with Mesoblast CEO, page-88

ARDS is using the same product as aGVHD and Crohns, the question is why do you think they need to pay a royalty to use it with ARDS? This is an extract from Mesoblast that details the Continuing Obligations.

Osiris Acquisition—Continuing ObligationsIn October 2013, we and Osiris entered into a purchase agreement, as amended, or the Osiris Purchase Agreement, under which we acquired all of Osiris’ business and assets related to culture expanded MSCs. Pursuant to the Osiris Purchase Agreement, we also agreed to make certain milestone and royalty payments to Osiris pertaining to MSC-100-IV for the treatment of aGVHD and Crohn’s disease

...